News

Adorial Limited augments C4X Discovery’s drug discovery engine

1 March, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces the acquisition of Adorial Limited together with its subsidiaries ("Adorial"), a privately held drug discovery company with a proprietary genetic technology platform for the identification of novel drug targets ("the Acquisition").

19 November, 2015 – C4X Discovery Holdings plc (“C4XD” or the “Company”), a leader in rational drug discovery and design, today announces the appointment of Dr Clive Dix as Executive Chairman.

6 November, 2015 – C4X Discovery Holdings plc (“C4XD”), a leader in rational drug discovery and design, announces that in accordance with AIM Rule 20, electronic copies of its Annual Report and Accounts for the year ended 31 July 2015 together with the Notice of Annual General Meeting and Form of Proxy are available from the Company's investor relations website at www.c4xdiscovery.com. Hard copies of the 2015 Annual Report and Accounts have been posted to shareholders today.

28 October, 2015 – C4X Discovery Holdings plc (“C4XD”), a leader in rational drug discovery and design, is pleased to announce its preliminary results for the year ended 31 July 2015.

28 October, 2015 – C4X Discovery Holdings plc (“C4XD”), a leader in rational drug discovery and design, is pleased to announce that it has entered into a research collaboration with the University of Oxford’s Structural Genomics Consortium department (“SGC-Oxford”).

Wednesday, 07 October 2015

Press Release Research update

Small molecule leads against IL-17 for inflammation and autoimmune diseases

7 October, 2015 – C4X Discovery Holdings plc (“C4XD”), a leader in rational drug discovery and design, is pleased to provide the following research update on key, highly selective small molecule leads in its programme against Interleukin-17 (IL-17), a critical and high value target in inflammation and autoimmune diseases.

Wednesday, 23 September 2015

Press Release Research update

Breakthrough compounds for diabetes and inflammation

23 September, 2015 – C4X Discovery Holdings plc (“C4XD”), a leader in rational drug discovery and design, is pleased to provide the following research update on recent key milestones in its programmes for Type 2 diabetes and inflammation, two areas of significant unmet medical need that represent large pharmaceutical markets.

3 September, 2015 – C4X Discovery Holdings plc (“C4XD” or “the Company”), a leader in rational drug discovery and design, today announced that it is further strengthening its team with two new management appointments.